“Our data demonstrates that UM cells are killed by treatment with aramchol plus regorafenib plus metformin via enhanced autophagic flux and that this combination may have the potential to control UM tumors that have metastasized to the liver.”
Cancer has long been understood through a variety of biological frameworks, including genetic mutations, dysregulated signaling pathways, and uncontrolled cell proliferation. Yet, these models often capture the visible consequences of disease rather than the deeper metabolic dependencies that sustain tumor survival. Despite major advances in targeted therapies, a central challenge remains: what underlying mechanisms make cancer cells vulnerable to treatment, and how can these vulnerabilities be exploited more effectively? Increasing attention has shifted toward cellular metabolism—particularly lipid regulation and energy-sensing pathways such as AMPK—as critical determinants of tumor behavior. Scientists are now taking a closer look at how metabolism works together with stress responses like autophagy—and how this connection could be used to develop better cancer treatments.
A new research paper was published in Volume 17 of Oncotarget, titled “The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.” The study was led by first author Michael R. Booth and corresponding author Paul Dent from Virginia Commonwealth University, in collaboration with Laurence Booth and Jane L. Roberts from Virginia Commonwealth University and John M. Kirkwood from the University of Pittsburgh Cancer Institute.
Targeting Tumor Metabolism Through Lipid Enzymes
Cancer cells rely heavily on metabolic reprogramming to sustain growth and survival. One enzyme of growing interest is stearoyl-CoA desaturase 1 (SCD1), which regulates lipid metabolism and cellular redox balance. Aramchol, an SCD1 inhibitor originally developed for metabolic liver disease, is being investigated as a potential strategy for targeting tumor metabolism.
In this study, researchers explored how aramchol behaves in combination with two clinically relevant agents: regorafenib, a multi-kinase inhibitor, and metformin, a widely used anti-diabetic drug known to activate AMPK signaling.
A Three-Drug Combination with Enhanced Anti-Tumor Activity
The findings reveal a clear hierarchy of therapeutic impact. While aramchol alone showed modest anti-tumor activity, its combination with regorafenib significantly increased tumor cell death. Notably, the addition of metformin further amplified this effect, producing the strongest response across multiple tumor models, including uveal melanoma (UM) and cholangiocarcinoma cells.
This enhanced killing effect was associated with coordinated signaling changes, including AMPK activation and suppression of mTOR-related pathways—key regulators of cellular energy balance and survival.
Autophagy: A Central Mechanism of Tumor Cell Death
A defining feature of the study is the identification of autophagic flux as a central mechanism underlying tumor cell killing.
Using LC3-based fluorescence assays, the authors demonstrated that the drug combination markedly increased the formation of autophagosomes and autolysosomes, indicating robust activation of macroautophagy. Importantly, silencing essential autophagy regulators such as Beclin1, ATG5, and LAMP2 significantly reduced both autophagic activity and tumor cell death.
These findings suggest that autophagy is an important functional component of therapeutic efficacy in this context.
Dual Mechanisms: Autophagy and Death Receptor Signaling
Beyond autophagy, the study also highlights a second critical pathway: death receptor signaling via BID.
The researchers showed that BID knockdown reduced tumor cell killing, supporting a role for BID-dependent death signaling alongside macroautophagy in the response to treatment. Together, these findings suggest that the drug combination engages multiple stress-response pathways that contribute to tumor cell death.
Re-Evaluating the Role of SCD1
Although aramchol targets SCD1, the study provides an important nuance: SCD1 inhibition alone does not fully explain the observed anti-cancer effects.
While SCD1 knockdown modestly increased baseline cell death, it did not replicate the full potency of the drug combination. This suggests that aramchol likely engages additional molecular targets or pathways, expanding its therapeutic relevance beyond lipid metabolism alone.
Implications for Uveal Melanoma and Liver Metastasis
Uveal melanoma is a rare but aggressive cancer with a strong tendency to metastasize to the liver—a site where treatment options remain limited. Because aramchol concentrates in the liver, the findings suggest that this combination may hold particular relevance for metastatic UM, which most often spreads to that organ.
Looking Ahead
This study provides preclinical evidence that combining aramchol, regorafenib, and metformin can significantly enhance tumor cell killing through coordinated metabolic and stress-response pathways.
Future work will be needed to validate these findings in vivo and determine their clinical applicability. However, the results already point toward a promising strategy: integrating metabolic targeting with established anti-cancer therapies to overcome resistance and improve efficacy.
Conclusion
By uncovering how SCD1 inhibition synergizes with kinase inhibition and metabolic modulation, this study advances a more integrated view of cancer therapy. Rather than relying on single-target approaches, the findings emphasize the power of multi-pathway disruption—combining autophagy, apoptosis, and metabolic stress—to drive tumor cell death.
Click here to read the full research paper published in Oncotarget.
_______
Oncotarget is an open-access, peer-reviewed journal that has published primarily oncology-focused research papers since 2010. These papers are available to readers (at no cost and free of subscription barriers) in a continuous publishing format at Oncotarget.com.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
